Vertex : EU Okays Casgevy For Sickle Cell Disease & Transfusion-Dependent Beta Thalassemia Treatment
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – The European Commission has granted conditional marketing authorization to Casgevy, a CRISPR/Cas9 gene-edited therapy. Casgevy is approved for the treatment of patients who are 12 years of age and older with severe sickle cell disease characterized by recurrent vaso-o
:max_bytes(150000):strip_icc():format(jpeg)/INV_SP500Gainers_Losers_2023_GettyImages-1223455297-196b1bea36f64240a70a0ce37ba6d1bc.jpg "Best Times of the Day, Week, and Month to Trade Stocks")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-172751278-cd584128c8ac48bbb99887a942f07eed.jpg "Why the Prices of Sports Tickets Vary So Much")
:max_bytes(150000):strip_icc():format(jpeg)/accountspayable.asp-Final-e4e5efa448a94289b6b17189aa72f10e.jpg "Are Accounts Payable an Expense?")